Antimicrobial Resistance: Problem Pathogens and Clinical CountermeasuresRobert C. Owens, Ebbing Lautenbach CRC Press, 22 dec 2007 - 520 pagina's This publication provides a state-of-the-art overview of key issues related to antimicrobial resistance, including a focus on key pathogens causing common healthcare-associated and community-acquired infections. The epidemiology and therapeutic considerations of these antimicrobial resistant organisms are discussed, as well as the clinical and heal |
Inhoudsopgave
| 1 | |
Its Utility in the Fight Against Antibacterial Resistance | 25 |
Opportunity or Obstacle for the Pharmaceutical Industry? | 39 |
Focus on Epidemiologic Methods | 61 |
Contemporary Antimicrobial Resistance Issues GramPositive GramNegative and Miscellaneous Pathogens | 75 |
Resistance Update and Treatment Options | 89 |
Resistance Update and Treatment Options | 111 |
Resistance Update and Treatment Options | 125 |
Chapter 14 Antimicrobial Cycling Programs | 251 |
Rationale for and Practical Considerations of Programmatic Institutional Efforts to Optimize Antimicrobial Use | 261 |
Chapter 16 ComputerAssisted Programs to Optimize Antimicrobial Use | 301 |
A Focus on BetaLactam Antibiotics | 317 |
Principles Current Data and Caveats | 337 |
Chapter 19 Impact of Guidelines on Antimicrobial Treatment of Respiratory Tract Infections | 371 |
Issues and Controversies | 397 |
What Is the Evidence? | 433 |
An Understanding of Resistance Issues | 149 |
An Update | 169 |
Overview and Update with a Focus on Antimicrobial Resistance as a Risk Factor | 183 |
Trends and Treatment Considerations for Candidemia | 219 |
Interventional Strategies to Combat Resistance | 231 |
Overige edities - Alles bekijken
Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures Robert C. Owens,Ebbing Lautenbach Gedeeltelijke weergave - 2007 |
Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures Robert C. Owens,Ebbing Lautenbach Geen voorbeeld beschikbaar - 2007 |
Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures Robert C. Owens,Ebbing Lautenbach Geen voorbeeld beschikbaar - 2020 |
Veelvoorkomende woorden en zinsdelen
Acinetobacter activity acute addition agents antibiotic Antimicrob Agents Chemother antimicrobial resistance antimicrobial therapy appropriate associated aureus bacteremia bacterial beta-lactam caused Center cephalosporins changes Clin Infect clinical clinicians Clostridium colonization combination compared cost cultures demonstrated difficile disease dose drug effective emergence empiric et al evaluated exposure fluoroquinolones Gram-negative guidelines healthcare hospital identified impact important improve increased Infect Control Infectious Diseases initial institutions Intern intervention isolates limited measures mechanisms Microbiol mortality nosocomial organisms outbreak outcomes pathogens patients penicillin period pneumonia population potential practice prescribing prevention producing Pseudomonas aeruginosa randomized rates received recent recommended reduce regimens reported require respiratory risk risk factors selection setting severe significant specific strains strategies surveillance susceptibility testing therapy tion tract treated treatment trial United vancomycin vitro